
Commentary|Videos|June 3, 2025
ASCO 2025: Top Data Highlights from 6/2
Author(s)Yan Leyfman, MD, Chandler Park, MD, MSc, FACP
Fact checked by: Kristi Rosa
MedNews Week hosts speak with 8 key opinion leaders at ASCO 2025 about the top data highlights of the day.
Advertisement
On the Clock is a dynamic video series from MedNews Week and OncLive, bringing you rapid-fire insights from top oncology experts at the 2025 ASCO Annual Meeting. In each episode, key opinion leaders share the data they’re most excited about—highlighting the studies, trends, and breakthroughs that could shape clinical practice.
In this episode, hosts Chandler Park, MD, FACP, and Yan Leyfman, MD, spoke with the following key opinion leaders:
- Liz O'Riordan, MD, PhD, FRCS, of Royal Marsden Hospital
- Laila Agrawal, MD, of Norton Cancer Institute
- Debora Barton, MD, of Full-Life Technologies
- Arya Roy, MD, of The Ohio State University Comprehensive Cancer Center–The James
- Kevin Kayvan Zarrabi, MD, MS, FACP, of Sidney Kimmel Comprehensive Cancer Center
- Pashtoon Kasi, MD, MS, of City of Hope
- Ann LaCasce, MD, MMSc, of Dana-Farber Cancer Institute
- Nina Shah, MD, of UCSF Health and AstraZeneca
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5



































